{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+or+Metastatic+Breast+Cancer&page=6", "query": { "condition": "Locally Advanced or Metastatic Breast Cancer", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 329, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+or+Metastatic+Breast+Cancer&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+or+Metastatic+Breast+Cancer&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T02:59:12.127Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04274933", "title": "A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Cancer" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2020-05-21", "completion_date": "2020-10-08", "has_results": false, "last_update_posted_date": "2020-10-29", "last_synced_at": "2026-10-12T02:59:12.127Z", "location_count": 11, "location_summary": "Joliet, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more", "locations": [ { "city": "Joliet", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04274933" }, { "nct_id": "NCT01783444", "title": "A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 309, "start_date": "2013-02-26", "completion_date": "2018-07-30", "has_results": true, "last_update_posted_date": "2021-02-26", "last_synced_at": "2026-10-12T02:59:12.127Z", "location_count": 19, "location_summary": "Los Angeles, California • San Diego, California • Fort Myers, Florida + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Burlington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01783444" }, { "nct_id": "NCT07062965", "title": "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PF-07248144", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-08-05", "completion_date": "2030-11-04", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-12T02:59:12.127Z", "location_count": 102, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07062965" }, { "nct_id": "NCT07454642", "title": "AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Vulvar Adenocarcinoma", "PDAC - Pancreatic Ductal Adenocarcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Small Cell Carcinoma of Lung", "Colorectal Cancer", "Hormone Receptor Positive Breast Carcinoma" ], "interventions": [ { "name": "AVA6103", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avacta Life Sciences Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2026-03-31", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-12T02:59:12.127Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Sarasota, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07454642" }, { "nct_id": "NCT03184558", "title": "Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer", "Inflammatory Breast Cancer Stage IV" ], "interventions": [ { "name": "Bemcentinib; pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BerGenBio ASA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2017-07-26", "completion_date": "2018-08-20", "has_results": true, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-10-12T02:59:12.127Z", "location_count": 5, "location_summary": "Duarte, California • San Diego, California • Kansas City, Missouri + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03184558" }, { "nct_id": "NCT00166543", "title": "Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "TAS-108", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SRI International", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 146, "start_date": "2004-05", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2015-08-18", "last_synced_at": "2026-10-12T02:59:12.127Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00166543" }, { "nct_id": "NCT02340221", "title": "A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Taselisib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 631, "start_date": "2015-04-09", "completion_date": "2021-06-29", "has_results": true, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-10-12T02:59:12.127Z", "location_count": 16, "location_summary": "Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02340221" }, { "nct_id": "NCT00006459", "title": "Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2000-07", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2012-06-07", "last_synced_at": "2026-10-12T02:59:12.127Z", "location_count": 31, "location_summary": "Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 27 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006459" }, { "nct_id": "NCT00246090", "title": "A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "E7389", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 298, "start_date": "2005-10", "completion_date": "2007-09", "has_results": true, "last_update_posted_date": "2014-07-14", "last_synced_at": "2026-10-12T02:59:12.127Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Verne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00246090" }, { "nct_id": "NCT02650401", "title": "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "CNS Tumors" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "0 Years to 18 Years" }, "enrollment_count": 69, "start_date": "2016-05-03", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-12T02:59:12.127Z", "location_count": 15, "location_summary": "La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650401" } ] }